Appili Therapeutics Announces Results of Annual and Extraordinary General Meeting of Shareholders

HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on developing therapeutics and countermeasures for infectious diseases, today announced the results of its annual and special general meeting of shareholders held earlier today.

Based on the proxies received and the vote taken at the meeting, all resolutions submitted were approved by the shareholders of the Company, including the election of the following directors for the next year: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Prakash Gowd.

The voting results for each director are summarized below:

Name and surname of the candidate	Percentage of votes in favor	Percentage of votes against
Don Cilla	27,929,188 (94.54%)	1,612,685 (5.46%)
Brian Bloom	28,409,188 (96.17%)	1,132,685 (3.83%)
Theresa Matkovits	29,377,973 (99.45%)	163,900 (0.55%)
Jurgen Froehlich	29,377,973 (99.45%)	163,900 (0.55%)
Armand Balboni	28,409,188 (96.17%)	1,132,685 (3.83%)
Prakash Gowd	29,377,973 (99.45%)	163,900 (0.55%)

All other matters considered at the Meeting were approved by shareholders, including the reappointment of PricewaterhouseCoopers, LLP, Chartered Accountants, as the Company’s independent auditors for a further year and the authorisation of the Company’s directors to fix their remuneration, a special resolution approving the continuation of the Company (the “Continuation”) from a regulated company under Canada Business Corporations Act to a corporation subject to Commercial Companies Act (Ontario) (the “OBCA”) and a special resolution authorizing the board of directors of the Company, pursuant to the Continuation, to determine from time to time the number of directors within the minimum and maximum number of directors specified in the articles of association of the Company, pursuant to Section 125(3) of the OBCA.

The Company has published on its SEDAR+ profile at www.sedarplus.ca a report on the voting results for all resolutions adopted at the General Meeting.

About Appili Therapeutics

Appili Therapeutics is a purpose-built, portfolio-driven, and people-focused infectious disease biopharmaceutical company dedicated to solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent death and improve lives. The company is currently developing a diverse portfolio of anti-infective agents, including an FDA-approved, off-the-shelf metronidazole suspension for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious bioweapons threat, and a topical antiparasitic agent to treat a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infections. For more information, visit www.AppiliTherapeutics.com.

Media contact:
Jenna McNeil, Corporate Affairs and Communications Manager
Appila Therapy
E: [email protected]

Contact for investors:
Don Cilla, Pharm.DMBA
Appila Therapy
E: [email protected]